Guardant Health rises
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening.
Guardant Health Shares Rise After ADLT Status for Shield Blood Test
Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that can't be obtained by any other method, and for FDA-approved tests.
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
(RTTNews) - Guardant Health, Inc. (GH) Tuesday announced that the Centers for Medicare & Medicaid Services or CMS has granted Advanced Diagnostic Laboratory Test or ADLT status to its Shield ...
The company highlighted the positive impact of the Advanced Diagnostic Laboratory Test (ADLT) status for SHIELD, while also addressing challenges in market penetration and operational efficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback